New genomic medicine institute to enhance precision, prevention, and personalized cancer treatment in India
Chandigarh, August 30:
In a major step towards revolutionizing cancer care in India, Fortis Hospital Mohali has launched the Institute of Genomic Medicine, offering world-class precision in diagnosis, prevention, and targeted treatment of cancer.
The initiative aims to identify genetic variations in genes, chromosomes, and DNA patterns that trigger cancer. By doing so, doctors can determine the risk of life-threatening complications early and recommend timely, customized therapies.
The institute will function under the leadership of Dr. Rajeev Bedi, Director, Medical Oncology, and Dr. Ravneet Kaur, Associate Consultant, Medical Genetics, supported by a team of specialists working on research-driven genomic techniques.
“Genomic testing typically begins with samples of blood, saliva, or tumor tissues. Using next-generation sequencing and liquid biopsy, we can study tumor genes, detect faulty wiring or mutations, and design therapies that are more effective while minimizing side effects,” explained Dr. Kaur at the launch.
This technology also identifies inherited genetic changes such as BRCA1/2 mutations, which may put patients and their families at a lifelong higher risk of developing certain cancers. Early detection allows for preventive screenings, lifestyle modifications, and timely interventions, ensuring proactive cancer care.
Highlighting the importance of genomics, Dr. Bedi added, “No two cancers are alike. With genomics, cancer therapy is moving from standard protocols to highly personalized solutions.”
The Institute of Genomic Medicine marks a significant advancement in India’s healthcare ecosystem, positioning Fortis Mohali as a leader in precision oncology and offering hope for thousands of cancer patients across the country.
